153 related articles for article (PubMed ID: 2383892)
1. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.
Felgar RE; Hiserodt JC
Cell Immunol; 1990 Sep; 129(2):288-98. PubMed ID: 2383892
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
Tjota A; Zhang YQ; Piedmonte MR; Lee CL
J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
Schwarz RE; Vujanovic NL; Hiserodt JC
Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals.
Kjaergaard J; Hokland ME; Agger R; Skovbo A; Nannmark U; Basse PH
Cancer Immunol Immunother; 2000 Jan; 48(10):550-60. PubMed ID: 10630307
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
7. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
8. In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells.
Maghazachi AA; Herberman RB; Vujanovic NL; Hiserodt JC
Cell Immunol; 1988 Aug; 115(1):179-94. PubMed ID: 3261203
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases.
Basse P; Herberman RB; Nannmark U; Johansson BR; Hokland M; Wasserman K; Goldfarb RH
J Exp Med; 1991 Aug; 174(2):479-88. PubMed ID: 1856630
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
13. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Rodolfo M; Salvi C; Bassi C; Parmiani G
Cancer Immunol Immunother; 1990; 31(1):28-36. PubMed ID: 2306753
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of lymphokine-activated killer (LAK) cells in Wag rats after hepatic-artery or jugular-vein infusion.
Kuppen PJ; Marinelli A; Camps JA; Pauwels EK; van de Velde CJ; Fleuren GJ; Eggermont AM
Int J Cancer; 1992 Sep; 52(2):266-70. PubMed ID: 1521913
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
17. Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo.
Lafreniere R; Rosenstein MS; Rosenberg SA
J Immunol Methods; 1986 Nov; 94(1-2):37-49. PubMed ID: 2878049
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
